Treating personality disorder in community mental health teams: Commentary on... Use of psychotropic medication among psychiatric out-patients with personality disorder

Psychiatrist

Volumn 34, Issue 3, 2010, Pages 86-88

  Duggan, Conor ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LITHIUM; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR;

BIPOLAR DISORDER; CLINICAL PRACTICE; COMMUNITY MENTAL HEALTH; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; MAJOR DEPRESSION; NOTE; OUTPATIENT CARE; PERSONALITY DISORDER; PRACTICE GUIDELINE; SCHIZOPHRENIA;

EID: 77951112369     PISSN: 17583209     EISSN: 17583217     Source Type: Journal    
DOI: 10.1192/pb.bp.109.026450     Document Type: Note

References (6)

1. National Institute for Health and Clinical Excellence. Borderline Personality Disorder: Treatment and Management. The British Psychological Society and The Royal College of Psychiatrists, 2009.
2. Tyrer P, Mitchard S, Methuen C, Ranger M. Treatment-rejecting and treatment-seeking personality disorders: Type R and Type S. J Pers Disord 2003; 17: 265-270
3. Swanson MC, Bland RC, Newman SC. Epidemiology of psychiatric disorders in Edmonton. Antisocial personality disorders. Acta Psychiatr Scand Suppl 1994; 376: 63-70.
4. Sanderson C, Clarkin JF. Further use of the NEO-Pi-R personality dimensions in differential treatment planning. In Personality Disorders and the Five Factor Model of Personality (2nd edn) (eds PT Costa, TA Widiger): 351-375 American Psychological Association Books, 2002.
5. Soloff PH. Symptom-orientated psychopharmacology for personality disorders. J Practical Psychiatr Behav Health 1998; 4: 3-11.
6. Reich JH, Green AI. Effect of personality disorders on outcome of treatment. J Nerv Ment Dis 1991; 192: 74-82.